Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial

被引:1
|
作者
Gruner, Laura Fiona [1 ,2 ]
Hoffmeister, Michael [1 ]
Ludwig, Leopold [3 ]
Brenner, Hermann [1 ,4 ,5 ,6 ]
机构
[1] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 581, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Heidelberg, Heidelberg, Germany
[3] Gastroentereol Schwerpunktpraxis, Dornstadt, Germany
[4] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Heidelberg, Germany
[6] German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany
来源
JMIR RESEARCH PROTOCOLS | 2020年 / 9卷 / 04期
关键词
colorectal cancer; early detection; screening; fecal immunochemical test (FIT); invitation; Germany; PARTICIPATION;
D O I
10.2196/16413
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Fecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low. Objective: The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years. Methods: This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy. Results: A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019. Conclusions: This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The Effects of Different Invitation Schemes on the Use of Fecal Occult Blood Tests for Colorectal Cancer Screening: Systematic Review of Randomized Controlled Trials
    Gruner, Laura F.
    Amitay, Efrat L.
    Heisser, Thomas
    Guo, Feng
    Niedermaier, Tobias
    Gies, Anton
    Hoffmeister, Michael
    Brenner, Hermann
    CANCERS, 2021, 13 (07)
  • [2] Fecal Immunochemical Tests for Colorectal Cancer Screening
    Daly, Jeanette
    AMERICAN JOURNAL OF NURSING, 2012, 112 (10) : 67 - 69
  • [3] Quantitative fecal immunochemical tests for colorectal cancer screening
    Gies, Anton
    Bhardwaj, Megha
    Stock, Christian
    Schrotz-King, Petra
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (02) : 234 - 244
  • [4] Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening
    Quintero, Enrique
    Carrillo, Marta
    Gimeno-Garcia, Antonio Z.
    Hernandez-Guerra, Manuel
    Nicolas-Perez, David
    Alonso-Abreu, Inmaculada
    Luisa Diez-Fuentes, Maria
    Abraira, Victor
    GASTROENTEROLOGY, 2014, 147 (05) : 1021 - +
  • [5] Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion A Randomized Clinical Trial
    Singal, Amit G.
    Gupta, Samir
    Skinner, Celette Sugg
    Ahn, Chul
    Santini, Noel O.
    Agrawal, Deepak
    Mayorga, Christian A.
    Murphy, Caitlin
    Tiro, Jasmin A.
    McCallister, Katharine
    Sanders, Joanne M.
    Bishop, Wendy Pechero
    Loewen, Adam C.
    Halm, Ethan A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (09): : 806 - 815
  • [6] Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests
    Meklin, Jannica
    Syrjanen, Kari
    Eskelinen, Matti
    ANTICANCER RESEARCH, 2020, 40 (02) : 575 - 581
  • [7] Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening
    Chen, Juan
    Lin, Jie
    Zhang, Lijing
    Chen, Mengshi
    Yu, Xunbin
    Wu, Yijuan
    Wang, Tao
    Xu, Rongrong
    Tian, Tian
    Sun, Aijuan
    Zhang, Tiantian
    Lu, Yan
    Ba, Zhaofen
    Cheng, Xiaowei
    Chen, Minghong
    CLINICAL LABORATORY, 2022, 68 (12) : 2446 - 2453
  • [8] Colorectal cancer screening: Why immunochemical fecal occult blood tests may be the best option
    Kathy L Flitcroft
    Les M Irwig
    Stacy M Carter
    Glenn P Salkeld
    James A Gillespie
    BMC Gastroenterology, 12
  • [9] Factors associated with false-positive fecal immunochemical tests in a large German colorectal cancer screening study
    Amitay, Efrat L.
    Cuk, Katarina
    Niedermaier, Tobias
    Weigl, Korbinian
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2419 - 2427
  • [10] Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening
    Chen, Juan
    Lin, Jie
    Zhang, Lijing
    Chen, Mengshi
    Yu, Xunbin
    Wu, Yijuan
    Wang, Tao
    Xu, Rongrong
    Tian, Tian
    Sun, Aijuan
    Zhang, Tiantian
    Lu, Yan
    Ba, Zhaofen
    Cheng, Xiaowei
    Chen, Minghong
    CLINICAL LABORATORY, 2022, : 2446 - 2453